Literature DB >> 21204914

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren.

Tuija Tapaninen1, Pertti J Neuvonen, Mikko Niemi.   

Abstract

AIM: The aim of this study was to investigate the effects of orange juice and apple juice on the pharmacokinetics and pharmacodynamics of aliskiren.
METHODS: In a randomized crossover study, 12 healthy volunteers ingested 200 ml of orange juice, apple juice or water three times daily for 5 days. On day 3, they ingested a single 150-mg dose of aliskiren. Plasma aliskiren concentrations were measured up to 72 h, its excretion into urine up to 12 h and plasma renin activity up to 24 h.
RESULTS: Orange and apple juice reduced aliskiren peak plasma concentrations by 80% (95% CI 63%, 89%, P < 0.001) and 84% (95% CI 72%, 91%, P < 0.001), and the area under the plasma aliskiren concentration-time curve (AUC) by 62% (95% CI 47%, 72%, P < 0.001) and 63% (95% CI 46%, 74%, P < 0.001), respectively, but had no significant effect on its elimination half-life or renal clearance. The decreases in aliskiren AUC by orange and apple juice correlated with aliskiren AUC during the water phase (r= 0.98, P < 0.001). Plasma renin activity was 87% and 67% higher at 24 h after aliskiren during the orange juice and apple juice phases, respectively, than during the water phase (P < 0.05).
CONCLUSIONS: Orange juice and apple juice greatly reduce the plasma concentrations and renin-inhibiting effect of aliskiren, probably by inhibiting its OATP2B1-mediated influx in the small intestine. Concomitant intake of aliskiren with orange or apple juice is best avoided.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21204914      PMCID: PMC3093077          DOI: 10.1111/j.1365-2125.2010.03898.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  44 in total

1.  Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.

Authors:  T Ikegawa; F Ushigome; N Koyabu; S Morimoto; Y Shoyama; M Naito; T Tsuruo; H Ohtani; Y Sawada
Journal:  Cancer Lett       Date:  2000-11-10       Impact factor: 8.679

Review 2.  Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

Authors:  David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

3.  Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Authors:  George K Dresser; David G Bailey; Brenda F Leake; Ute I Schwarz; Paul A Dawson; David J Freeman; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

4.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.

Authors:  I Tamai; J Nezu; H Uchino; Y Sai; A Oku; M Shimane; A Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

5.  Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol.

Authors:  Jari J Lilja; Janne T Backman; Jouko Laitila; Harri Luurila; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

6.  Determination of phenolic acids and flavonoids of apple and pear by high-performance liquid chromatography.

Authors:  A Schieber; P Keller; R Carle
Journal:  J Chromatogr A       Date:  2001-03-02       Impact factor: 4.759

7.  Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.

Authors:  Tuija Tapaninen; Janne T Backman; Kaisa J Kurkinen; Pertti J Neuvonen; Mikko Niemi
Journal:  J Clin Pharmacol       Date:  2010-04-16       Impact factor: 3.126

8.  Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction.

Authors:  Ashley L Neuhofel; John H Wilton; Jennifer M Victory; Linda G Hejmanowsk; Guy W Amsden
Journal:  J Clin Pharmacol       Date:  2002-04       Impact factor: 3.126

9.  Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.

Authors:  Daisuke Kobayashi; Takashi Nozawa; Kozue Imai; Jun-ichi Nezu; Akira Tsuji; Ikumi Tamai
Journal:  J Pharmacol Exp Ther       Date:  2003-04-30       Impact factor: 4.030

10.  Structure-based design of aliskiren, a novel orally effective renin inhibitor.

Authors:  Jeanette M Wood; Jürgen Maibaum; Joseph Rahuel; Markus G Grütter; Nissim-Claude Cohen; Vittorio Rasetti; Heinrich Rüger; Richard Göschke; Stefan Stutz; Walter Fuhrer; Walter Schilling; Pascal Rigollier; Yasuchika Yamaguchi; Frederic Cumin; Hans-Peter Baum; Christian R Schnell; Peter Herold; Robert Mah; Chris Jensen; Eoin O'Brien; Alice Stanton; Martin P Bedigian
Journal:  Biochem Biophys Res Commun       Date:  2003-09-05       Impact factor: 3.575

View more
  20 in total

1.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.

Authors:  Yoshiyuki Shirasaka; Takanori Mori; Yukiko Murata; Takeo Nakanishi; Ikumi Tamai
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

3.  Renin and cardiovascular disease: Worn-out path, or new direction.

Authors:  Gaurav Alreja; Jacob Joseph
Journal:  World J Cardiol       Date:  2011-03-26

Review 4.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

5.  Interaction between Warfarin and Apple Juice.

Authors:  May Choi; Marcy Mintz; Duane Bates
Journal:  Can J Hosp Pharm       Date:  2016 Jan-Feb

Review 6.  Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.

Authors:  Eric Judd; Edgar A Jaimes
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-03

7.  Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.

Authors:  Sam Rebello; Sally Zhao; Sam Hariry; Marion Dahlke; Natalya Alexander; Arpine Vapurcuyan; Imad Hanna; Venkateswar Jarugula
Journal:  Eur J Clin Pharmacol       Date:  2011-11-29       Impact factor: 2.953

8.  Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.

Authors:  Yumiko Akamine; Masatomo Miura; Hisakazu Komori; Shun Saito; Hiroyuki Kusuhara; Ikumi Tamai; Ichiro Ieiri; Tsukasa Uno; Norio Yasui-Furukori
Journal:  Eur J Clin Pharmacol       Date:  2014-06-07       Impact factor: 2.953

9.  Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice.

Authors:  Emily J Johnson; Christina S Won; Kathleen Köck; Mary F Paine
Journal:  Biopharm Drug Dispos       Date:  2017-02-14       Impact factor: 1.627

Review 10.  Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Pharmacol Ther       Date:  2012-08-04       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.